To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 423 participants.
Also called NCT05702073
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 423 participants
- Registry
-
NCT05702073
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05702073. Randomized; no masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-06-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- INS068 injection
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct05702073- Content hash
9530e9b74de34e623352231557eebc97213c9749d3e45ba789cfd9a12618a90e